Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
British multinational pharmaceutical company GlaxoSmithKline (GSK) divides its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Ablynx currently has more than 45 proprietary and partnered programs for the development of new treatments in the therapeutic areas of hematology, inflammation, respiratory disease, oncology, and immuno-oncology.
On January 22, 2018, Sanofi announced that it had entered into an agreement with Bioverativ to acquire all of its outstanding shares for $105 per share in cash.
AstraZeneca’s (AZN) cardiovascular and metabolics diseases segment’s revenues are expected to decrease in 4Q17 due to lower sales of Crestor and Byetta.
In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.
Teva Pharmaceutical plans to increase the prices of certain products in its portfolio since the current prices are cited as unsustainable by the company.
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type two diabetes mellitus.
In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.
In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.
GlaxoSmithKline’s (GSK) global pharmaceuticals business is a part of the pharmaceuticals segment. It reported revenues of 3.24 billion pounds during 2Q17.
On March 2, 2016, combination therapy Faslodex and palbociclib was approved by the FDA for HR+ human epidermal growth factor receptor 2 negative (or HER2) metastatic breast cancer.
